Company intelligence / Profile preview

Plano Pharms

Houston, Texas, United States

Ownership: Private
Development stage: Other

Overview

Plano Pharms is a biotechnology company focused on developing small molecule therapeutics that target the Integrated Stress Response (ISR) pathway to treat neurodegenerative and neurodevelopmental disorders. Founded on the pioneering research of Dr. Mauro Costa-Mattioli, the company explores the use of ISR inhibitors to restore protein synthesis and enhance cognitive function. Their primary focus includes conditions such as Down syndrome, Alzheimer's disease, and traumatic brain injury, where ISR dysregulation is a key pathological feature. Plano Pharms aims to translate breakthrough discoveries in proteostasis into life-changing medicines for patients with cognitive deficits.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Plano Pharms.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plano Pharms.

Explore the full profile